UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052806
Receipt number R000060164
Scientific Title Treatment patterns and clinical situation in patients with idiopathic thrombocytopenic purpura (ITP) in Japan: a retrospective claims database study
Date of disclosure of the study information 2023/11/15
Last modified on 2024/02/27 20:57:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Treatment patterns and clinical situation in patients with idiopathic thrombocytopenic purpura (ITP) in Japan: a retrospective claims database study

Acronym

Treatment patterns and clinical situation in patients with idiopathic thrombocytopenic purpura (ITP) in Japan: a retrospective claims database study

Scientific Title

Treatment patterns and clinical situation in patients with idiopathic thrombocytopenic purpura (ITP) in Japan: a retrospective claims database study

Scientific Title:Acronym

Treatment patterns and clinical situation in patients with idiopathic thrombocytopenic purpura (ITP) in Japan: a retrospective claims database study

Region

Japan


Condition

Condition

Idiopathic thrombocytopenic purpura

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the clinical situation of medication in patients with idiopathic thrombocytopenic purpura in Japan, especially corticosteroid prescriptions and their adverse events, and to identify issues related to their medication.

Basic objectives2

Others

Basic objectives -Others

N/A

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1.Clinical situation of corticosteroid medication
2.Clinical situation of medication and treatment other than corticosteroid
3.Treatment patterns

Key secondary outcomes

Adverse events in corticosteroid medication


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The study population consists of the patients diagnosed with idiopathic thrombocytopenic purpura in the DeSC Claims Database between April 2014 and August 2022 for this study

Key exclusion criteria

Patients with suspected secondary idiopathic thrombocytopenic purpura (splenomegaly, hematologic cancers, hematologic system diseases, immune disorders, malignant tumors)
Patients with idiopathic thrombocytopenic purpura complicating pregnancy
Patients with acute idiopathic thrombocytopenic purpura

Target sample size

4000


Research contact person

Name of lead principal investigator

1st name Seiichiro
Middle name
Last name Nyui

Organization

KISSEI PHARMACEUTICAL CO., LTD.

Division name

Medical

Zip code

103-0022

Address

1-8-9, Nihonbashimuromachi, Chuo-ku, Tokyo

TEL

03-3279-2306

Email

ikuyaku@pharm.kissei.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Kanenishi

Organization

INTAGE Healthcare Inc.

Division name

Epidemiological study group, Real-World evidence department, Medical evidence division

Zip code

101-0062

Address

13F Ochanomizu SolaCity 4-6 Kanda-Surugadai, Chiyoda-ku, Tokyo

TEL

03-5294-8393

Homepage URL


Email

kanenishi-m@intage.com


Sponsor or person

Institute

KISSEI PHARMACEUTICAL CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Non-Profit Organization MINS

Address

20-9-401, Mita 5-chome, Minato-ku, Tokyo

Tel

03-6416-1868

Email

npo-mins@j-irb.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 11 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 21 Day

Date of IRB

2023 Year 09 Month 25 Day

Anticipated trial start date

2023 Year 09 Month 25 Day

Last follow-up date

2023 Year 12 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

[Analysis Contracting Organization]
Intage Healthcare Inc.

[Database Provider]
DeSC Healthcare, Inc.


Management information

Registered date

2023 Year 11 Month 15 Day

Last modified on

2024 Year 02 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060164


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name